Effects of aripiprazole on subjective and physiological responses to alcohol

Alcoholism: Clinical and Experimental Research

Volumn 32, Issue 4, 2008, Pages 573-579

  Kranzler, Henry R ^a,b   Covault, Jonathan ^b   Pierucci Lagha, Amira ^b   Chan, Grace ^b   Douglas, Kara ^b   Arias, Albert J ^b   Oncken, Cheryl ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Alcohol Research Center   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol Administration; Aripiprazole; Human Laboratory Study; Physiological Effects of Alcohol; Subjective Effects of Alcohol

Indexed keywords

ALCOHOL; ARIPIPRAZOLE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ATAXIA; BLOOD PRESSURE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFECT; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SLEEP DISORDER; SOMNOLENCE; UNITED STATES;

ADULT; ALCOHOL DRINKING; BLOOD PRESSURE; BREATH TESTS; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES;

EID: 41149142001     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2007.00608.x     Document Type: Article

References (41)

1. Anton RF, Kranzler HR, Breder C, Marcus RN, Carson WH, Han J (2008) A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 28: 5 12.
2. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L (2005) Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 66: 756 760.
3. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381 389.
4. Davidson D, Hutchison K, Dagon C, Swift R (2002) Assessing the stimulant effects of alcohol in humans. Pharmacol Biochem Behav 72: 151 156.
5. DeLeon A, Patel NC, Crimson ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26: 649 666.
6. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID - I/P, Version 2.0), Biometrics Research Department, New York State Psychiatric Institute, New York.
7. Holdstock L, de Wit H (1998) Individual differences in the biphasic effects of ethanol. Alcohol Clin Exp Res 22: 1903 1911.
8. Holdstock L, King AC, de Wit H (2000) Subjective and objective responses to ethanol in moderate/heavy and light social drinkers. Alcohol Clin Exp Res 24: 789 794.
9. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R (2006) The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31: 1310 1317.
10. Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A (2001) Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology 155: 27 34.
11. Ingman K, Kupila J, Hyytia P, Korpi ER (2006) Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 41: 391 398.
12. Inoue T, Domae M, Yamada K, Furukawa T (1996) Effects of the novel antipsychotic agent 7- (4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277: 137 143.
13. Janca A, Bucholz KK, Janca I (1997) Family History Assessment Module. Washington University of School Medicine, Department of Psychiatry, St. Louis, MO.
14. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441: 137 140.
15. Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O'Brien CP (2007) A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol 27: 344 351.
16. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763 771.
17. Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus RN, Sanchez R, Aripiprazole Study Group (2006) A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67: 626 637.
18. Kenna GA (2003) Rationale for use of aripiprazole for alcohol dependence treatment. Drugs Future 28: 1227 1235.
19. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329 336.
20. King AC, Houle T, de Wit H, Holdstock L, Schuster A (2002) Biphasic alcohol response differs in heavy versus light drinkers. Alcohol Clin Exp Res 26: 827 835.
21. Koob GF, Rassnick S, Heinrichs S, Weiss F (1994) Alcohol, the reward system and dependence. EXS 71: 103 114.
22. Kornetsky C, Bain GT, Unterwald EM, Lewis KJ (1988) Brain stimulation reward: effects of ethanol. Alcohol Clin Exp Res 12: 609 616.
23. Li TK (2000) Clinical perspectives for the study of craving and relapse in animal models. Addiction 95 (Suppl. 2 S55 60.
24. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61: 123 136.
25. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM (1993) Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res 17: 140 146.
26. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245 258.
27. Martinotti G, Nicola MD, Janiri L (2007) Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 33: 393 401.
28. McBride WJ, Li TK (1998) Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. Crit Rev Neurobiol 12: 339 369.
29. McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikychi T (2002) Aripiprazole: a Dopamine-Serotonin System Stabilizer. Int J Neuropsychopharmacol 5 (Suppl. I S176.
30. Modell JG, Mountz JM, Glaser FB, Lee JY (1993) Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res 17: 234 240.
31. Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I (2004) Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol 24: 532 535.
32. Myers RD, Robinson DE (1999) Mmu and D2 receptor antisense oligonucleotides injected in nucleus accumbens suppress high alcohol intake in genetic drinking HEP rats. Alcohol 18: 225 233.
33. Myrick H, Anton RF, Li X, Henderson S, Voronin K, George MS (2006) The effect of aripiprazole on cue-induced brain activation in alcoholics. Neuropsychopharmacology 31: S90.
34. Nevo I, Hamon M (1995) Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 26: 305 336 discussion 337-342.
35. O'Malley S, Maisto S (1984) Factors affecting the perception of intoxication: dose, tolerance, and setting. Addict Behav 9: 111 120.
36. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG (2003) Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 64: 1048 1056.
37. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T, Aripiprazole Study Group (2006) Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 20: 536 546.
38. Sobell L, Sobell M (1992) Timeline follow-back, a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption (Litten R, Allen J, ed), pp 41 72. The Humana Press, Inc., Totowa.
39. Söderpalm AH, de Wit H (2002) Effects of stress and alcohol on subjective state in humans. Alcohol Clin Exp Res 26: 818 826.
40. Thomas SE, Drobes DJ, Voronin K, Anton RF (2004) Following alcohol consumption, nontreatment-seeking alcoholics report greater stimulation but similar sedation compared with social drinkers. J Stud Alcohol 65: 330 335.
41. Warsi M, Sattar SP, Bhatia SC, Petty F (2005) Aripiprazole reduces alcohol use. Can J Psychiatry 50: 244.